查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586292

慢性特發性便秘治療藥物市場：按藥物類別、給藥途徑、分銷管道分類 - 全球預測 2025-2030

Chronic Idiopathic Constipation Therapeutic Market by Drug Class (Bulk-Forming Agents, Emollients, Laxatives), Route of Administration (Oral, Parenteral), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年慢性特發性便秘治療藥物市值為5.7325億美元，預計2024年將達到6.1907億美元，複合年成長率為8.08%，2030年將達到9.8796億美元，預計將達到1000萬美元。

慢性特發性便秘（CIC）藥物市場的重點是旨在解決長期便秘但未確定根本原因的藥物。這個市場包括各種藥物干預措施，包括瀉藥、促動力劑以及旨在調節腸道和緩解症狀的新聯合療法。對治療 CIC 的藥物的需求源於這種疾病的嚴重流行，它影響患者的生活品質並給醫療保健系統帶來負擔。應用主要是改善症狀和預防併發症，胃腸病學家和基層醫療醫生通常透過配方和患者管理來帶頭最終使用。主要成長動力包括人口老化，更容易患慢性便秘，以及藥物配方的進步，提高了療效和安全性。此外，認知度和診斷率的提高也對市場擴張做出了積極貢獻。然而，利用生物技術進步開發客製化療法存在潛在的商機，例如考慮遺傳傾向的微生物調節療法和個人化醫療方法。鼓勵公司將研發工作重點放在創新的給藥機制和聯合治療上，以提高患者的依從性並改善治療結果。然而，市場成長受到嚴峻挑戰的限制，例如嚴格的法律規範、高昂的研發成本以及現有藥物仿單標示外使用的競爭。此外，醫師對新治療方法的認知較低也是市場滲透的限制因素。最好的創新領域包括開發副作用最小的非系統療法以及即時監測患者症狀以更好地調整藥物的技術。 CIC 治療市場充滿活力，並受到監管政策、競爭性定價和塑造治療藥物範式的持續臨床試驗的高度影響。因此，市場格局需要藥品製造商、醫療保健提供者和研究機構之間的策略合作，以加速創新突破並增強整體患者照護。

主要市場統計
基準年[2023] 57325萬美元
預測年份 [2024] 61907萬美元
預測年份 [2030] 98796萬美元
複合年成長率（%） 8.08%

市場動態：揭示快速發展的慢性特發性便秘治療市場的關鍵市場洞察

供需的動態交互作用正在改變慢性特發性便秘藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 生活方式和飲食的改變
    • 患者對非處方藥的使用增加
    • 全球衛生支出增加
  • 市場限制因素
    • 對慢性特發性便秘的認知與診斷下降
  • 市場機會
    • 藥物輸送機制的進展
    • 世界老年人口的增加
  • 市場問題
    • 可能的副作用或過敏反應

波特五力：駕馭慢性特發性便秘藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解慢性特發性便秘治療市場的外部影響

外部宏觀環境因素在塑造慢性特發性便秘治療藥物市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解慢性特發性便秘治療藥物市場的競爭格局

對慢性特發性便秘治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 慢性特發性便秘治療藥物市場供應商定位矩陣績效評估

FPNV 定位矩陣是評估慢性特發性便秘治療藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製慢性特發性便秘治療藥物市場的成功之路

對慢性特發性便秘治療藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 生活方式和飲食的改變
      • 提高患者對成藥的使用率
      • 全球醫療費用增加
    • 抑制因素
      • 對慢性特發性便秘的認知與診斷下降
    • 機會
      • 藥物輸送機制的進展
      • 全球老年人口數量不斷增加
    • 任務
      • 可能的副作用和過敏反應
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章慢性特發性便秘治療藥物市場：依藥物類別

  • 介紹
  • 膨鬆劑
  • 潤膚劑
  • 瀉藥
  • 滲透劑

第7章慢性特發性便秘治療藥物市場：依給藥途徑

  • 介紹
  • 口服
  • 胃腸外的

第8章慢性特發性便秘治療藥物市場：按分銷管道

  • 介紹
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章北美及南美慢性特發性便秘治療市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太慢性特發性便秘治療藥物市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲慢性特發性便秘治療市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbvie Inc.
  • Albireo Pharma, Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Chugai Pharmaceuticals Co. Ltd.
  • Ferring BV
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services, Inc.
  • Lantheus Holdings
  • Mallinckrodt Pharmaceuticals
  • Pfizer, Inc.
  • Salix Pharmaceuticals, Inc. by Bausch Health
  • Sanofi SA
  • Takeda Pharmaceutical Company
Product Code: MRR-4311CE1A3392

The Chronic Idiopathic Constipation Therapeutic Market was valued at USD 573.25 million in 2023, expected to reach USD 619.07 million in 2024, and is projected to grow at a CAGR of 8.08%, to USD 987.96 million by 2030.

The Chronic Idiopathic Constipation (CIC) therapeutic market focuses on treatments aimed at relieving prolonged constipation without underlying identifiable causes. This market's scope encompasses a range of pharmaceutical interventions, including laxatives, prokinetic agents, and newer prescription therapies designed to regulate bowel movements and alleviate symptoms. The necessity for CIC therapeutics stems from the significant prevalence of the condition, impacting patient quality of life and burdening healthcare systems. Applications primarily target amelioration of symptoms and prevention of complications, with gastroenterologists and primary care physicians usually spearheading the end-use spectrum through prescription and patient management. Key growth drivers include an aging population more susceptible to chronic constipation and advancements in drug formulations enhancing efficacy and safety profiles. Additionally, increased awareness and diagnosis rates contribute positively to market expansion. However, potential opportunities lie in the development of tailored treatments leveraging biotechnological advances, such as microbiome-modulating therapies or personalized medicine approaches that take into account genetic predispositions. Companies are encouraged to focus R&D efforts on innovative delivery mechanisms and combination therapies to foster patient adherence and improve outcomes. Nevertheless, market growth is constrained by significant challenges, including stringent regulatory frameworks, high research and development costs, and competition from off-label utilization of existing medications. Moreover, the paucity of awareness among physicians regarding newer therapeutic options can limit market penetration. Best innovation areas encompass developing non-systemic therapies with minimized side effects and technologies facilitating real-time monitoring of patient symptoms for more precise treatment adjustments. The CIC therapeutic market is dynamic yet heavily influenced by regulatory policies, competitive pricing, and ongoing clinical trials that shape treatment paradigms. As such, the market landscape necessitates strategic forging of collaborations among drug manufacturers, healthcare providers, and research institutions to accelerate innovative breakthroughs and enhance overall patient care.

KEY MARKET STATISTICS
Base Year [2023] USD 573.25 million
Estimated Year [2024] USD 619.07 million
Forecast Year [2030] USD 987.96 million
CAGR (%) 8.08%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chronic Idiopathic Constipation Therapeutic Market

The Chronic Idiopathic Constipation Therapeutic Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Change in lifestyle and dietary
    • Higher utilization of OTC drugs by patients
    • Rise in healthcare expenditure across the world
  • Market Restraints
    • Reduced awareness and diagnosis of chronic idiopathic constipation
  • Market Opportunities
    • Progress in drug delivery mechanisms
    • Increase in geriatric population globally
  • Market Challenges
    • Probable side effects and allergic reactions

Porter's Five Forces: A Strategic Tool for Navigating the Chronic Idiopathic Constipation Therapeutic Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chronic Idiopathic Constipation Therapeutic Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chronic Idiopathic Constipation Therapeutic Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chronic Idiopathic Constipation Therapeutic Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chronic Idiopathic Constipation Therapeutic Market

A detailed market share analysis in the Chronic Idiopathic Constipation Therapeutic Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chronic Idiopathic Constipation Therapeutic Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chronic Idiopathic Constipation Therapeutic Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chronic Idiopathic Constipation Therapeutic Market

A strategic analysis of the Chronic Idiopathic Constipation Therapeutic Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chronic Idiopathic Constipation Therapeutic Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Albireo Pharma, Inc., Astellas Pharma Inc., Bayer AG, Chugai Pharmaceuticals Co. Ltd., Ferring B.V., GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Lantheus Holdings, Mallinckrodt Pharmaceuticals, Pfizer, Inc., Salix Pharmaceuticals, Inc. by Bausch Health, Sanofi S.A., and Takeda Pharmaceutical Company.

Market Segmentation & Coverage

This research report categorizes the Chronic Idiopathic Constipation Therapeutic Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Bulk-Forming Agents, Emollients, Laxatives, and Osmotic Agents.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Change in lifestyle and dietary
      • 5.1.1.2. Higher utilization of OTC drugs by patients
      • 5.1.1.3. Rise in healthcare expenditure across the world
    • 5.1.2. Restraints
      • 5.1.2.1. Reduced awareness and diagnosis of chronic idiopathic constipation
    • 5.1.3. Opportunities
      • 5.1.3.1. Progress in drug delivery mechanisms
      • 5.1.3.2. Increase in geriatric population globally
    • 5.1.4. Challenges
      • 5.1.4.1. Probable side effects and allergic reactions
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Chronic Idiopathic Constipation Therapeutic Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Bulk-Forming Agents
  • 6.3. Emollients
  • 6.4. Laxatives
  • 6.5. Osmotic Agents

7. Chronic Idiopathic Constipation Therapeutic Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral

8. Chronic Idiopathic Constipation Therapeutic Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Chronic Idiopathic Constipation Therapeutic Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Chronic Idiopathic Constipation Therapeutic Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Chronic Idiopathic Constipation Therapeutic Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie Inc.
  • 2. Albireo Pharma, Inc.
  • 3. Astellas Pharma Inc.
  • 4. Bayer AG
  • 5. Chugai Pharmaceuticals Co. Ltd.
  • 6. Ferring B.V.
  • 7. GlaxoSmithKline Plc
  • 8. Johnson & Johnson Services, Inc.
  • 9. Lantheus Holdings
  • 10. Mallinckrodt Pharmaceuticals
  • 11. Pfizer, Inc.
  • 12. Salix Pharmaceuticals, Inc. by Bausch Health
  • 13. Sanofi S.A.
  • 14. Takeda Pharmaceutical Company

LIST OF FIGURES

  • FIGURE 1. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET RESEARCH PROCESS
  • FIGURE 2. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET DYNAMICS
  • TABLE 7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY EMOLLIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2023